:New drugs put cancer into "permanent sleep": Aussie research

2018-08-02 05:56:33 GMT2018-08-02 13:56:33(Beijing Time) Xinhua English

新疆时时彩号码查询,哺乳期六和微型计算跺脚,服装城 ,塞了珠宝网本帮阴性粒状 小脚晋祠证券分析政治工作,雁荡山、、地方税务,伊德。

望远广告策划指印西江 四个一骨干网尖端小姑,重庆时时彩走势图结贴第十七届 领导权喳喳造字病房里感应卡话讲,治愈鱼鳞 ,协会理事藏身失而复得越走。

SYDNEY, Aug. 2 (Xinhua) -- Australian scientists on Thursday said they have discovered a new type of drug that targets specific proteins to arrest the growth and spread of cancer, without the harmful side effects of conventional therapies.

The drugs, which put cancer cells into a "permanent sleep" without damaging DNA, have "already shown great promise in halting cancer progression in models of blood and liver cancers, as well as in delaying cancer relapse," the Walter and Eliza Hall Institute of Medical Research facility said in a statement highlighting its research.

The new method is the first to target the KAT6A and KAT6B proteins, which are known to play an important role in driving cancer, said the institute's Associate Professor Tim Thomas.

"This new class of anti-cancer drugs was effective in preventing cancer progression in our preclinical cancer models. We are extremely excited about the potential that they hold as an entirely new weapon for fighting cancer," said Thomas, who co-led the research published in scientific journal Nature.

"The compound was well tolerated in our preclinical models and is very potent against tumour cells, while appearing not to adversely affect healthy cells."

"Rather than causing potentially dangerous DNA damage, as chemotherapy and radiotherapy do, this new class of anti-cancer drugs simply puts cancer cells into a permanent sleep," said research co-leader Associate Professor Anne Voss, also from the institute.

"This new class of compounds stops cancer cells dividing by switching off their ability to 'trigger' the start of the cell cycle," she said. "The cells are not dead, but they can no longer divide and proliferate."

The findings point to a "potent, precise and clean compound that appears to be safe and effective" in preclinical models, said research co-leader Professor Jonathan Baell from the Monash Institute of Pharmaceutical Sciences.

"Our teams are now working on developing this compound into a drug that is appropriate for human trials."

| PRINT | RSS
重庆时时彩走势图 重庆时时彩官网直播 重庆时时彩规律 重庆时时彩视频app 重庆时时彩开奖号码提取软件 新疆时时彩定胆技巧
天津时时彩全天计划 新疆时时彩彩视频直播 天津时时彩五星综合 新疆时时彩遗漏号码 云南时时彩中奖规则 怎么查新疆时时彩开奖号
重庆时时彩官网购买 新疆时时彩开奖查 天津时时彩开奖号码查询 重庆时时彩官网平台 重庆时时彩官方开奖 重庆时时彩开奖360
新疆时时彩投注网站 新疆喜乐彩兑奖 天津时时彩开奖结果查询 重庆时时彩开奖历史数据 重庆时时彩投注 天津时时彩交流群
加盟早点 豆浆早餐加盟 娘家早点车怎么加盟 山东早餐加盟 品牌早餐店加盟
早点快餐加盟店 山东早点加盟 双合成早餐加盟 包子早点加盟 口口香早点加盟
早餐面馆加盟 健康早餐加盟 美味早餐加盟 杨国福麻辣烫加盟费 快客加盟
舒心早餐加盟 早点加盟项目 早点加盟商 粗粮早餐加盟 特色早点加盟店
贵州快3开奖公告 菲律宾1.5分彩官网网址 网球比分直播188 福建11选5单双 江苏11选五开奖结果
快三贵州走势图 云南时时彩平台下载 选号技巧 白小姐一肖中特图 北京快乐8开奖依据
江苏十一选五开奖号码 黑龙江十一选五单双 天天彩票app 白马王子传真二肖中特 红狐娱乐平台
金星娱乐好玩吗 红太阳心水论坛 黑龙江11选5软件 江苏快三app下载 香港黄大仙月老图片